Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis.
Gloria KimRenxin ChuFawad YousufShahamat TauhidLynn StazzoneMaria K HoutchensJames M StankiewiczChristopher SeversonDorlan KimbroughFrancisco J QuintanaTanuja ChitnisHoward L WeinerBrian C HealyRohit BakshiPublished in: The International journal of neuroscience (2017)
DGM atrophy may prove efficient as a short-term outcome for proof-of-concept neurotherapeutic trials in PMS.